Abstract
Several clinical trials have now demonstrated that when patients with chronic HCV genotype 1 are treated with the combination of a protease inhibitor, peginterferon and ribavirin SVR is significantly greater compared to treatment with peginterferon and ribavirin. In treatment naïve patients SVR is increased from approximately 45% to 69–75%. The duration of treatment can be shortened in approximately 60% of the patients. In experienced patients SVR rates are approximately 50%. Two protease inhibitors, telaprevir and boceprevir, have now completed phase 3 clinical trials and should be approved by regulatory bodies in many countries during 2011. These two medications are associated with adverse events over and above those observed with peginterferon and ribavirin including worsening anemia, rash and dysgusia. Numerous other protease and polymerase inhibitors are currently being evaluated in phase 3 clinical trials. The combination of multiple direct acting anti-viral agents along with peginteferon and ribavirin may allow treatment to be shortened in many patients while still achieving high rates of SVR in the future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- DAAs:
-
Direct acting antivirals
- SVR:
-
Sustained virological response
- RVR:
-
Rapid virological response
- PEG-IFN:
-
Pegylated-interferon
- RBV:
-
Ribavirin
References
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.
Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131:1040–8.
McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–93.
Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122–6.
Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135(3):821–9.
Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30(9):1259–69.
Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther. 2009;14(4):501–11.
Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2008;57(4):516–24.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:391–401.
Asselah T, Essioux L, Marcellin P, et al. (2010) A chromosome 19 SNP (RS12979860) predicts outcome (EVR/SVR) in HCV patients treated with interferon, independent of pegylation or ribavirin. J Hepatol 2010; EASL: A1180.
Asselah T. Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol. 2010;52(3):452–4.
Asselah T, Marcellin P. New direct-acting antivirals combination for the treatment of chronic hepatitis C. Liver Int. 2011;31(1)68–77.
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.
Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–50.
Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon Alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 illuminate study. Hepatology 52, AASLD 2010; Abstract LB-2.
McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292–303.
Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 advance study. Hepatology 52, AASLD 2010; Abstract 211.
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.
Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140(2):459–68.
Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705–16.
Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.
Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol. 2005;43:453–71.
Shiffman ML. What future for ribavirin? Liver Int. 2009;29 Suppl 1:68–73.
Berg T, Mchutchison JG, Adda N, et al. SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null response, partial response, viral breakthrough or relapse after PR. In: 45th annual meeting of the European Association for the study of the liver (EASL 2010), 14–18 April 2010.
Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–17.
Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–75.
Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naïve, genotype 1 HCV subjects. Hepatology 2010; 52; AASLD 2010, Abstract LB-1.
Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52(3):822–32.
Zeuzem S, Asselah T, Angus PW, et al. Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients with Chronic HCV infection. Gastroenterlogy. 2011, in press.
Lok AS, Gardiner DF, Lawitz E, et al. Quadriple therapy with BMS-790052, BMS-650032 and pegIFN/RBV for 24 weeks results in 100% SVR 12 in HCV genotype 1 null responders. J Hepatol. 2011;54(S1):S536.
Jensen DM, Wedemeyer H, Herring RW, et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study. Hepatology 2010; 52; AASLD 2010, Abstract 81.
Lalezari JP, O’Riordan W, Poordad F, et al. A phase IIa study of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment-naïve HCV genotype 1-infected subjects. Hepatology 2010; 52; AASLD 2010, Abstract 34.
Lawitz E, Gaultier I, Poordad F, et al. ABT-450/Ritonavir (ABT-450/R) combined with pegylated interferon alpha 2a and ribavirin (SOC) after 3-day monotherapy in genotype 1 HCV infected treatment naïve subjects: 12 week interim efficacy and safety results. J Hepatol. 2011;54(S1):S482.
Brainard DM, Petry A, Anderson MS, et al. Safety, tolerability, and pharmacokinetics ater single and multiple doses of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in healthy subjects. Hepatology 2010; 52; AASLD 2010, Abstract 1885.
Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PEG-IFN/RBV in a phase 2b trial: rapid virologic suppression intreatment naïve patients with HCV GT2/GT3. J Hepatol. 2011;54(S1):S28.
Sulkowski MS, Ceasu E, Asselah T, et al. SILEN-C1: sustained virological response and safety of BI201335 combined with Peginterferon alfa 2a and ribavirin in treatment naïve patients with chronic genotype 1 HCV infection. J Hepatol. 2011;54 Suppl 1:S27.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Marcellin, P., Boyer, N., Asselah, T. (2012). Peginterferon, Ribavirin and Anti-viral Triple Therapy. In: Shiffman, M. (eds) Chronic Hepatitis C Virus. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1192-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1192-5_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1191-8
Online ISBN: 978-1-4614-1192-5
eBook Packages: MedicineMedicine (R0)